• HPB (Oxford) · Apr 2020

    ALPPS in neuroendocrine liver metastases not amenable for conventional resection - lessons learned from an interim analysis of the International ALPPS Registry.

    • Michael Linecker, Patryk Kambakamba, Dimitri A Raptis, Massimo Malagó, Francesca Ratti, Luca Aldrighetti, Ricardo Robles-Campos, Nadja Lehwald-Tywuschik, Wolfram T Knoefel, Deniz Balci, Victoria Ardiles, E... more duardo De Santibañes, Stéphanie Truant, Francois-René Pruvot, Gregor A Stavrou, Karl J Oldhafer, Sergey Voskanyan, Basant Mahadevappa, Ivan Kozyrin, Jee K Low, Valentina Ferrri, Emilio Vicente, Andreas Prachalias, Michail Pizanias, Ashley K Clift, Henrik Petrowsky, Pierre-Alain Clavien, and Andrea Frilling. less
    • Swiss HPB and Transplantation Center, Department of Surgery, University Hospital Zurich, Switzerland.
    • HPB (Oxford). 2020 Apr 1; 22 (4): 537-544.

    BackgroundSurgery is the most effective treatment option for neuroendocrine liver metastases (NELM). This study investigated the role of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) as a novel strategy in treatment of NELM.MethodsThe International ALPPS Registry was reviewed to study patients who underwent ALPPS for NELM.ResultsFrom 2010 to 2017, 954 ALPPS procedures from 135 international centers were recorded in the International ALPPS Registry. Of them, 24 (2.5%) were performed for NELM. Twenty-one patients entered the final analysis. Overall grade ≥3b morbidity was 9% after stage 1 and 27% after stage 2. Ninety-day mortality was 5%. R0 resection was achieved in 19 cases (90%) at stage 2. Median follow-up was 28 (19-48) months. Median disease free survival (DFS) was 17.3 (95% CI: 7.1-27.4) months, 1-year and 2-year DFS was 73.2% and 41.8%, respectively. Median overall survival (OS) was not reached. One-year and 2-year OS was 95.2% and 95.2%, respectively.ConclusionsALPPS appears to be a suitable strategy for inclusion in the multimodal armamentarium of well-selected patients with neuroendocrine liver metastases. In light of the morbidity in this initial series and a high rate of disease-recurrence, the procedure should be taken with caution.Copyright © 2019 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

      Pubmed     Free full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.